Market closedNon-fractional
MiNK Therapeutics/INKT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About MiNK Therapeutics
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.
Ticker
INKT
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
New York, United States
Employees
31
Website
minktherapeutics.com
INKT Metrics
BasicAdvanced
$37M
Market cap
-
P/E ratio
-$0.60
EPS
0.05
Beta
-
Dividend rate
Price and volume
Market cap
$37M
Beta
0.05
Financial strength
Current ratio
0.54
Quick ratio
0.524
Long term debt to equity
-20.747
Total debt to equity
-20.747
Management effectiveness
Return on assets (TTM)
-111.24%
Return on equity (TTM)
166.18%
Valuation
Price to book
-1.6
Price to tangible book (TTM)
-1.6
Price to free cash flow (TTM)
-2.294
Growth
Earnings per share change (TTM)
-22.49%
3-year earnings per share growth (CAGR)
-2.98%
What the Analysts think about INKT
Analyst Ratings
Majority rating from 4 analysts.
INKT Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$3.8M
-29.63%
Profit margin
0.00%
NaN%
INKT Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.18
-$0.15
-$0.16
-$0.11
-
Expected
-$0.20
-$0.18
-$0.15
-$0.15
-$0.10
Surprise
-8.86%
-17.81%
4.35%
-28.26%
-
INKT News
AllArticlesVideos
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
GlobeNewsWire·2 months ago
MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting
GlobeNewsWire·2 months ago
MiNK Reports First Quarter 2024 Results
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for MiNK Therapeutics stock?
MiNK Therapeutics (INKT) has a market cap of $37M as of July 27, 2024.
What is the P/E ratio for MiNK Therapeutics stock?
The price to earnings (P/E) ratio for MiNK Therapeutics (INKT) stock is 0 as of July 27, 2024.
Does MiNK Therapeutics stock pay dividends?
No, MiNK Therapeutics (INKT) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next MiNK Therapeutics dividend payment date?
MiNK Therapeutics (INKT) stock does not pay dividends to its shareholders.
What is the beta indicator for MiNK Therapeutics?
MiNK Therapeutics (INKT) has a beta rating of 0.05. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell MiNK Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.